GRAL GRAIL Inc.

$GRAL odd reference with this ’test’ i asked my Doc, may i please have a test done, she said the CEO of Mayo Clinic (little man from Italy) has determined the Grail test for ’executive only’ WOW no wonder he’s done. This test will change the way we attack ’Cancer’ $IBRX & $SLS for cancer maintenance

$GRAL Sorry shorts, you are fried now. only way out is to cover. Gral is headed to $20B market cap within 2-3 years on strong demand and adoption worldwide especially for multiple cancers which have zero screening today. It will surpass Guardant Health market cap $25B in a few years. Marketing has been designed by Gral team, Hims and Hers and Samsung and many others. Galleri test is a gift to humanity and it will only get better (more sensitive) over time with machine learning. new data from post marketing surveillance and ongoing trials will answer many unanswered questions to date for broader adoption. Cheers to all!

Guardant’s Shield: the FDA advisory panel voted **8–1 on safety, 6–3 on effectiveness, and 7–2 on benefit-risk**. The FDA subsequently **approved Shield on July 26, 2024**. For investors, the takeaway is simple: 10–0 on safety, 6–4 on effectiveness, and 7–2 on benefit-risk is an exceptionally strong outcome for GRAIL. The panel clearly supported Galleri across all three FDA voting questions. $GRAL

$GRAL stocks go up on future vakue, not based on present vakue. Grail is getting priced for upcoming FDA approval and Rapid CMS coverage which will facilitate blockbuster revenue growth starting 2027 Q2. It will be at $8B market cap by then and keep going up as revenue exceeds expectations quarter over quarter going forward. New data will validate and strengthen clinical utility over nezt 2 years. As more cancers with no screening get detected, prescribing trends will catapult.

$GRAL Nine green days in a row with one day off along that path due to the stock being halted before the FDA announcement from the advisory committee recommendation. Up another 6.8% today, an example of how you sometimes have to buy on intraday pullbacks to add exposure (you should have a clear reason to do so however; a catalyst that is going to be bought)...

$GRAL I suspect a lot of people commenting on the 10–0, 6–4 and 7–2 votes simply don't have much experience following FDA device advisory panels. These panels are not designed to produce three unanimous votes. Members vote separately on safety, effectiveness and benefit-risk precisely because reasonable experts can reach different conclusions on different questions. Galleri won ALL THREE votes: Safety: **10–0 YES** Effectiveness: **6–4 YES** Benefit-risk: **7–2 YES** ADCOM was a great win for GRAIL

$GRAL Public hearings conckuded: 19 in strong favor with heart warming testimonies, 1 has some reservations and 2 opposed. The two who opposed are researches and idealists. willing to wait 20 years if that what it takes to develop and ideal test and meantime deny access and benefit to millions

A group of FDA advisers said Wednesday that the benefits of Grail’s Galleri blood test, which screens for signals associated with 50 types of cancer, outweigh its risks, marking an important step in the company’s effort to secure FDA approval and potentially broader insurance coverage. Galleri is a multicancer early-detection test that uses a blood draw to look for signals associated with different types of cancer. The advisers’ assessment could help advance Grail’s regulatory application, although an FDA decision is still required before the test could receive approval. FDA approval is particularly important because it could influence whether Medicare and other health insurers decide to cover Galleri. Wider insurance reimbursement could significantly expand access to the test beyond its current use, particularly among consumers interested in early cancer detection. The development comes as interest in multicancer detection technologies grows. $GRAL

$GRAL in since $105, thesis is too strong - approval for the only & only cancer radar detector test. Worldwide adoption - worldwide adoption - worldwide adoption soon - $250 soon then - $400 - $700🔥

$GRAL This stock saved my bacon this month . Had a miserable month trading . GRAL was like a runaway freight train the past two weeks. Very low float so they will have to split the stock down the road .

$GRAL The market thinks the answer on FDA approval will be yes. We find out on Sept. 23rd... Up +22.2% today...

$GRAL Agree with heavy c73. I own the stock and have been buying calls . I bought 2 oct. puts today as a hedge . Options are expensive because it’ so volatile . Check this out: I go to this new Dr. last week because my previous retired ( I wish him well ) so at the end of my appt . I ask him what he thinks about the Galleri test . Guys looks at me like i’m from Mars . He has no clue about the test . He has been practicing for over 30 yr. I told him I took the test over 2 years ago . Told him I own the Stock too . This company and stock is still very much under the radar . My primary knew about the test over two years ago .

$GRAL larryr15, I’ve read that GRAL is presenting Six abstracts sometime between Oct 6-8 . So They may have already presented . As far as price action , remember how the news leaked out before the FDA advisory panel meeting ?

$GRAL (2) Data across both meetings will include: A rapid oral presentation highlighting the efficiency and safety of Cancer Signal Origin (CSO) guided diagnostic workups. A poster showing Galleri cancer detection of more than 200 cancers across histologically distinct cancer types, including rare cancers. A poster showing Galleri cancer detection performance and accuracy across self-reported racial and ethnic groups. A poster presenting new NHS-Galleri data on the preclinical window for cancer detection with findings compatible with annual MCED screening. A poster showing a reduction of cancer diagnoses in emergency presentations associated with annual Galleri screenings.

$GRAL I was just watching Fox News and they were talking about a company is coming out with a test for cancer and the blood called the Galleria test. It was on Fox News approximately five minutes ago.

$GRAL Q2 revenue was only $44.7M while the company posted a $110.2M net loss and a $90.3M adjusted EBITDA loss. Even with Galleri growth, the core business remains deeply cash-burning, and the NHS-Galleri trial did not significantly reduce the combined Stage III/IV cancer endpoint

$GRAL So many people swore up and down that it was done immediately after the NHS trial results came out. Sometimes it pays to think and dig deep and not just react to surface headline info.

$GRAL $GRAL $118 now and volume continues to build. We’re right at the $118.84 52-week high. Clear that and then $120 with volume and hold above it, and we’re in breakout territory. This is exactly what I’ve been waiting for.

$GRAL $GRAL Don’t trust the $106 premarket price. Liquidity is extremely thin right now and the bid/ask spread is massive. The FDA panel vote was strongly positive: 10-0 safety, 6-4 effectiveness and 7-2 benefit/risk with 1 abstention. Let the market open and the orders fill in. $118.84 is the first major resistance I’m watching.

$GRAL The panel votes are in. Galleri looks safe (10-0), and benefits outweigh risks (7-2, one abstention). The number that matters is effectiveness: 6-4. Four of ten voting members weren't convinced. The FDA's own briefing docs asked the same question the no-voters did: 12-month sensitivity of 31-35%, most Stage I cancers missed. Is that really an "early detection" test? Trading resumed this morning roughly flat around $108.50 vs the $107.97 close. Monday's +34% had priced a clean win.